Annual Net Income
-$276.06 M
+$92.14 M+25.03%
31 December 2023
Summary:
Nektar Therapeutics annual net profit is currently -$276.06 million, with the most recent change of +$92.14 million (+25.03%) on 31 December 2023. During the last 3 years, it has risen by +$168.38 million (+37.89%). NKTR annual net income is now -140.52% below its all-time high of $681.31 million, reached on 31 December 2018.NKTR Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$37.06 M
+$15.31 M+29.23%
30 September 2024
Summary:
Nektar Therapeutics quarterly net profit is currently -$37.06 million, with the most recent change of +$15.31 million (+29.23%) on 30 September 2024. Over the past year, it has increased by +$8.78 million (+19.15%). NKTR quarterly net income is now -103.81% below its all-time high of $971.46 million, reached on 30 June 2018.NKTR Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$168.30 M
+$8.78 M+4.96%
30 September 2024
Summary:
Nektar Therapeutics TTM net profit is currently -$168.30 million, with the most recent change of +$8.78 million (+4.96%) on 30 September 2024. Over the past year, it has increased by +$125.36 million (+42.69%). NKTR TTM net income is now -118.64% below its all-time high of $902.71 million, reached on 30 June 2018.NKTR TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +25.0% | +19.1% | +42.7% |
| 3 y3 years | +37.9% | +71.4% | +66.0% |
| 5 y5 years | -140.5% | +62.4% | +60.6% |
NKTR Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +47.3% | -0.7% | +76.7% | at high | +67.9% |
| 5 y | 5 years | -140.5% | +47.3% | -0.7% | +76.7% | at high | +67.9% |
| alltime | all time | -140.5% | +47.3% | -103.8% | +76.7% | -118.6% | +67.9% |
Nektar Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$37.06 M(-29.2%) | -$168.30 M(-5.0%) |
| June 2024 | - | -$52.36 M(+42.3%) | -$177.08 M(+0.7%) |
| Mar 2024 | - | -$36.80 M(-12.5%) | -$175.84 M(-36.3%) |
| Dec 2023 | -$276.06 M(-25.0%) | -$42.08 M(-8.2%) | -$276.06 M(-6.0%) |
| Sept 2023 | - | -$45.84 M(-10.3%) | -$293.67 M(-4.3%) |
| June 2023 | - | -$51.12 M(-62.7%) | -$306.88 M(-26.0%) |
| Mar 2023 | - | -$137.02 M(+129.6%) | -$414.82 M(+12.7%) |
| Dec 2022 | -$368.20 M(-29.7%) | -$59.69 M(+1.1%) | -$368.20 M(-18.9%) |
| Sept 2022 | - | -$59.05 M(-62.9%) | -$454.15 M(-13.5%) |
| June 2022 | - | -$159.07 M(+76.0%) | -$524.81 M(+6.8%) |
| Mar 2022 | - | -$90.39 M(-37.9%) | -$491.26 M(-6.2%) |
| Dec 2021 | -$523.84 M(+17.9%) | -$145.65 M(+12.3%) | -$523.84 M(+5.7%) |
| Sept 2021 | - | -$129.71 M(+3.3%) | -$495.39 M(+4.5%) |
| June 2021 | - | -$125.52 M(+2.1%) | -$474.27 M(+10.6%) |
| Mar 2021 | - | -$122.97 M(+4.9%) | -$428.76 M(-3.5%) |
| Dec 2020 | -$444.44 M(+0.9%) | -$117.20 M(+7.9%) | -$444.44 M(+1.1%) |
| Sept 2020 | - | -$108.59 M(+35.7%) | -$439.40 M(+2.3%) |
| June 2020 | - | -$80.00 M(-42.3%) | -$429.40 M(-6.6%) |
| Mar 2020 | - | -$138.65 M(+23.6%) | -$459.69 M(+4.3%) |
| Dec 2019 | -$440.67 M(-164.7%) | -$112.16 M(+13.8%) | -$440.67 M(+3.3%) |
| Sept 2019 | - | -$98.58 M(-10.6%) | -$426.71 M(+0.6%) |
| June 2019 | - | -$110.29 M(-7.8%) | -$424.27 M(-164.5%) |
| Mar 2019 | - | -$119.63 M(+21.8%) | $657.47 M(-3.5%) |
| Dec 2018 | $681.31 M(-804.6%) | -$98.21 M(+2.2%) | $681.31 M(-8.6%) |
| Sept 2018 | - | -$96.14 M(-109.9%) | $745.70 M(-17.4%) |
| June 2018 | - | $971.46 M(-1114.1%) | $902.71 M(-801.9%) |
| Mar 2018 | - | -$95.79 M(+183.2%) | -$128.62 M(+33.0%) |
| Dec 2017 | -$96.69 M(-37.0%) | -$33.83 M(-155.6%) | -$96.69 M(-8.0%) |
| Sept 2017 | - | $60.87 M(-201.7%) | -$105.06 M(-49.8%) |
| June 2017 | - | -$59.87 M(-6.3%) | -$209.16 M(+5.7%) |
| Mar 2017 | - | -$63.87 M(+51.3%) | -$197.89 M(+28.9%) |
| Dec 2016 | -$153.52 M(+89.1%) | -$42.20 M(-2.4%) | -$153.52 M(-7.2%) |
| Sept 2016 | - | -$43.22 M(-11.1%) | -$165.46 M(+26.8%) |
| June 2016 | - | -$48.60 M(+149.3%) | -$130.44 M(-3.0%) |
| Mar 2016 | - | -$19.50 M(-64.0%) | -$134.50 M(+65.7%) |
| Dec 2015 | -$81.18 M(+50.6%) | -$54.14 M(+560.0%) | -$81.18 M(+11.6%) |
| Sept 2015 | - | -$8.20 M(-84.4%) | -$72.72 M(-1295.1%) |
| June 2015 | - | -$52.66 M(-255.7%) | $6.08 M(-76.7%) |
| Mar 2015 | - | $33.82 M(-174.0%) | $26.11 M(-148.4%) |
| Dec 2014 | -$53.92 M(-66.7%) | -$45.68 M(-164.7%) | -$53.92 M(-3.5%) |
| Sept 2014 | - | $70.61 M(-316.3%) | -$55.89 M(-60.9%) |
| June 2014 | - | -$32.64 M(-29.4%) | -$143.04 M(-6.6%) |
| Mar 2014 | - | -$46.20 M(-3.1%) | -$153.15 M(-5.5%) |
| Dec 2013 | -$162.01 M(-5.7%) | -$47.66 M(+188.1%) | -$162.01 M(-3.1%) |
| Sept 2013 | - | -$16.54 M(-61.3%) | -$167.28 M(-13.9%) |
| June 2013 | - | -$42.75 M(-22.4%) | -$194.28 M(+4.6%) |
| Mar 2013 | - | -$55.06 M(+4.0%) | -$185.82 M(+8.1%) |
| Dec 2012 | -$171.85 M(+28.3%) | -$52.93 M(+21.5%) | -$171.85 M(+9.9%) |
| Sept 2012 | - | -$43.55 M(+27.0%) | -$156.42 M(+14.2%) |
| June 2012 | - | -$34.28 M(-16.6%) | -$136.94 M(-1.5%) |
| Mar 2012 | - | -$41.10 M(+9.6%) | -$139.04 M(+3.8%) |
| Dec 2011 | -$133.98 M(+253.1%) | -$37.49 M(+55.8%) | -$133.98 M(+12.5%) |
| Sept 2011 | - | -$24.07 M(-33.8%) | -$119.06 M(+14.8%) |
| June 2011 | - | -$36.38 M(+1.0%) | -$103.71 M(+52.9%) |
| Mar 2011 | - | -$36.03 M(+59.6%) | -$67.84 M(+78.8%) |
| Dec 2010 | -$37.94 M(-63.0%) | -$22.58 M(+159.2%) | -$37.94 M(+64.7%) |
| Sept 2010 | - | -$8.71 M(+1584.9%) | -$23.03 M(-49.1%) |
| June 2010 | - | -$517.00 K(-91.6%) | -$45.29 M(-41.1%) |
| Mar 2010 | - | -$6.13 M(-20.1%) | -$76.84 M(-25.0%) |
| Dec 2009 | -$102.52 M | -$7.68 M(-75.2%) | -$102.52 M(+467.6%) |
| Sept 2009 | - | -$30.97 M(-3.4%) | -$18.06 M(-25.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$32.07 M(+0.8%) | -$24.13 M(-5.1%) |
| Mar 2009 | - | -$31.81 M(-141.4%) | -$25.44 M(-25.9%) |
| Dec 2008 | -$34.34 M(+4.8%) | $76.78 M(-307.3%) | -$34.34 M(-52.4%) |
| Sept 2008 | - | -$37.04 M(+11.0%) | -$72.08 M(+34.3%) |
| June 2008 | - | -$33.38 M(-18.0%) | -$53.66 M(+12.3%) |
| Mar 2008 | - | -$40.70 M(-204.3%) | -$47.79 M(+45.9%) |
| Dec 2007 | -$32.76 M(-78.8%) | $39.04 M(-309.7%) | -$32.76 M(-70.4%) |
| Sept 2007 | - | -$18.62 M(-32.3%) | -$110.66 M(-0.9%) |
| June 2007 | - | -$27.51 M(+7.2%) | -$111.64 M(-24.0%) |
| Mar 2007 | - | -$25.67 M(-33.9%) | -$146.96 M(-5.0%) |
| Dec 2006 | -$154.76 M(-16.4%) | -$38.85 M(+98.2%) | -$154.76 M(-31.0%) |
| Sept 2006 | - | -$19.60 M(-68.8%) | -$224.15 M(-1.8%) |
| June 2006 | - | -$62.83 M(+87.7%) | -$228.34 M(+18.7%) |
| Mar 2006 | - | -$33.47 M(-69.1%) | -$192.42 M(+3.9%) |
| Dec 2005 | -$185.11 M(+81.7%) | -$108.24 M(+354.9%) | -$185.11 M(+92.5%) |
| Sept 2005 | - | -$23.80 M(-11.6%) | -$96.14 M(+3.6%) |
| June 2005 | - | -$26.91 M(+2.9%) | -$92.80 M(+5.4%) |
| Mar 2005 | - | -$26.16 M(+35.8%) | -$88.05 M(-13.6%) |
| Dec 2004 | -$101.89 M(+118.3%) | -$19.27 M(-5.8%) | -$101.89 M(+28.8%) |
| Sept 2004 | - | -$20.45 M(-7.7%) | -$79.10 M(+4.3%) |
| June 2004 | - | -$22.16 M(-44.6%) | -$75.86 M(+13.7%) |
| Mar 2004 | - | -$40.00 M(-1239.0%) | -$66.73 M(+43.0%) |
| Dec 2003 | -$46.68 M(-56.6%) | $3.51 M(-120.4%) | -$46.68 M(-42.6%) |
| Sept 2003 | - | -$17.21 M(+32.0%) | -$81.27 M(-10.3%) |
| June 2003 | - | -$13.04 M(-34.6%) | -$90.58 M(-11.5%) |
| Mar 2003 | - | -$19.95 M(-35.8%) | -$102.36 M(-4.8%) |
| Dec 2002 | -$107.47 M(-57.0%) | -$31.07 M(+17.2%) | -$107.47 M(-4.6%) |
| Sept 2002 | - | -$26.52 M(+6.9%) | -$112.65 M(-0.4%) |
| June 2002 | - | -$24.82 M(-1.0%) | -$113.05 M(-41.7%) |
| Mar 2002 | - | -$25.06 M(-30.9%) | -$194.02 M(-22.4%) |
| Dec 2001 | -$250.01 M(+156.7%) | -$36.25 M(+34.7%) | -$250.01 M(-1.3%) |
| Sept 2001 | - | -$26.92 M(-74.6%) | -$253.37 M(+5.7%) |
| June 2001 | - | -$105.79 M(+30.5%) | -$239.66 M(+60.2%) |
| Mar 2001 | - | -$81.04 M(+104.6%) | -$149.61 M(+53.6%) |
| Dec 2000 | -$97.40 M(+153.3%) | -$39.61 M(+199.7%) | -$97.40 M(+25.0%) |
| Sept 2000 | - | -$13.21 M(-16.1%) | -$77.94 M(+8.7%) |
| June 2000 | - | -$15.75 M(-45.4%) | -$71.73 M(+15.7%) |
| Mar 2000 | - | -$28.83 M(+43.1%) | -$61.98 M(+61.5%) |
| Dec 1999 | -$38.45 M(+109.5%) | -$20.15 M(+187.8%) | -$38.37 M(+56.1%) |
| Sept 1999 | - | -$7.00 M(+16.7%) | -$24.58 M(+8.9%) |
| June 1999 | - | -$6.00 M(+14.9%) | -$22.58 M(+16.2%) |
| Mar 1999 | - | -$5.22 M(-17.8%) | -$19.43 M(+5.9%) |
| Dec 1998 | -$18.36 M(+83.9%) | -$6.36 M(+27.1%) | -$18.36 M(+22.5%) |
| Sept 1998 | - | -$5.00 M(+75.4%) | -$14.99 M(+18.6%) |
| June 1998 | - | -$2.85 M(-31.3%) | -$12.64 M(+4.6%) |
| Mar 1998 | - | -$4.15 M(+38.8%) | -$12.09 M(+21.1%) |
| Dec 1997 | -$9.98 M(-0.2%) | -$2.99 M(+12.8%) | -$9.98 M(-3.9%) |
| Sept 1997 | - | -$2.65 M(+15.4%) | -$10.39 M(+3.5%) |
| June 1997 | - | -$2.30 M(+12.4%) | -$10.04 M(-2.0%) |
| Mar 1997 | - | -$2.04 M(-39.9%) | -$10.24 M(+1.4%) |
| Dec 1996 | -$10.00 M(+29.9%) | -$3.40 M(+47.8%) | -$10.10 M(+12.2%) |
| Sept 1996 | - | -$2.30 M(-8.0%) | -$9.00 M(+7.1%) |
| June 1996 | - | -$2.50 M(+31.6%) | -$8.40 M(+12.0%) |
| Mar 1996 | - | -$1.90 M(-17.4%) | -$7.50 M(-3.8%) |
| Dec 1995 | -$7.70 M(+45.3%) | -$2.30 M(+35.3%) | -$7.80 M(0.0%) |
| Sept 1995 | - | -$1.70 M(+6.3%) | -$7.80 M(+11.4%) |
| June 1995 | - | -$1.60 M(-27.3%) | -$7.00 M(+11.1%) |
| Mar 1995 | - | -$2.20 M(-4.3%) | -$6.30 M(+21.2%) |
| Dec 1994 | -$5.30 M | -$2.30 M(+155.6%) | -$5.20 M(+79.3%) |
| Sept 1994 | - | -$900.00 K(0.0%) | -$2.90 M(+45.0%) |
| June 1994 | - | -$900.00 K(-18.2%) | -$2.00 M(+81.8%) |
| Mar 1994 | - | -$1.10 M | -$1.10 M |
FAQ
- What is Nektar Therapeutics annual net profit?
- What is the all time high annual net income for Nektar Therapeutics?
- What is Nektar Therapeutics annual net income year-on-year change?
- What is Nektar Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly net income year-on-year change?
- What is Nektar Therapeutics TTM net profit?
- What is the all time high TTM net income for Nektar Therapeutics?
- What is Nektar Therapeutics TTM net income year-on-year change?
What is Nektar Therapeutics annual net profit?
The current annual net income of NKTR is -$276.06 M
What is the all time high annual net income for Nektar Therapeutics?
Nektar Therapeutics all-time high annual net profit is $681.31 M
What is Nektar Therapeutics annual net income year-on-year change?
Over the past year, NKTR annual net profit has changed by +$92.14 M (+25.03%)
What is Nektar Therapeutics quarterly net profit?
The current quarterly net income of NKTR is -$37.06 M
What is the all time high quarterly net income for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly net profit is $971.46 M
What is Nektar Therapeutics quarterly net income year-on-year change?
Over the past year, NKTR quarterly net profit has changed by +$8.78 M (+19.15%)
What is Nektar Therapeutics TTM net profit?
The current TTM net income of NKTR is -$168.30 M
What is the all time high TTM net income for Nektar Therapeutics?
Nektar Therapeutics all-time high TTM net profit is $902.71 M
What is Nektar Therapeutics TTM net income year-on-year change?
Over the past year, NKTR TTM net profit has changed by +$125.36 M (+42.69%)